To assess the role of increased apelin and/or APJ expression in response of ovarian cancer patients to anti-angiogenic therapy, we evaluated the differences in disease-free survival (DFS) in patients treated with bevacizumab, who expressed variable levels of the genes. The gene discussed is APLN; the disease is ovarian carcinoma.